RxDoctor Payments Data

Kellie Wheeler, PA

Hospitalist · Burlington, MANPI 1629590187

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 40.0% of the total. 2024 is the largest year on record at $758, 2.3 times the $325 reported in 2022. Among hospitalist clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,336in general payments, 2019–2025

Across 56 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$535
  • Takeda Pharmaceuticals U.S.A., Inc.$235
  • Johnson & Johnson$201
  • Bristol Myers Squibb$141
  • AbbVie$95
  • Sanofi$64
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$1,336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,336 in reported general payments places this provider in the 95th percentile of 599 hospitalist providers in Massachusetts.

See all hospitalist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$32,230
Medicare patients
209
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin21$52,127
LinzessLinaclotide57$32,460
SutabSod Sulf/Pot Chloride/Mag Sulf31$5,056
Colestipol Hcl48$3,695
Omeprazole198$2,740
Pantoprazole Sodium95$1,584
Dicyclomine Hcl56$939
Sulfasalazine DrSulfasalazine20$909
Azathioprine11$744
Famotidine56$737
Sucralfate13$599
Lansoprazole18$258
Amitriptyline Hcl19$216
Ondansetron OdtOndansetron14$175
Ondansetron Hcl15$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$535$52,12721 claims
AbbVieLinzess$95$32,46057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 599 hospitalist providers in Massachusetts.

Other hospitalist in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →